NEXALIN TECHNOLOGY INC. news, videos and press releases
For more news please use our advanced search feature.
NEXALIN TECHNOLOGY INC. - More news...
NEXALIN TECHNOLOGY INC. - More news...
- Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
- Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
- Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
- Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
- Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
- Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
- Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
- Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
- Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
- New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
- Nexalin Technology CEO Provides Letter to Shareholders
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
- Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
- Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
- Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
- New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
- Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
- Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
- Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
- Nexalin Technology Announces Closing of $5.2 Million Public Offering
- Nexalin Technology Announces Pricing of $5.2 Million Public Offering
- Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
- Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
- Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
- Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
- FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
- Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
- Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
